By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) 

75 Sidney Street, 4th Floor

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-299-5000 Fax: 617-995-4995


Key Statistics

Ownership: Public

Web Site: AVEO Oncology
Symbol: AVEO


Merck & Co.  Cancer

Company News
AVEO Oncology (AVEO) Reports Second Quarter 2017 Financial Results And Provides Business Update 8/9/2017 6:45:08 AM
AVEO Oncology (AVEO) Announces $14 Million In Aggregate Gross Proceeds From Hercules Credit Facility And At-The-Market Stock Offerings 6/27/2017 10:10:01 AM
AVEO Oncology (AVEO) Announces Positive CHMP Opinion For Tivozanib As A Treatment Of Advanced Renal Cell Carcinoma 6/26/2017 12:01:03 PM
AVEO Oncology (AVEO) Announces Pivotal Phase III TIVO-3 Study Of Tivozanib In Renal Cell Carcinoma Reaches Enrollment Target 6/20/2017 6:01:37 AM
AVEO Oncology (AVEO) Announces Phase I/II Tinivo Trial Of Tivozanib And Opdivo (Nivolumab) In RCC Advances To Phase II 6/8/2017 6:58:59 AM
AVEO Oncology (AVEO) And Biodesix, Inc. Announce Results From Two Investigator-Sponsored Phase I Studies Of HGF Targeted Antibody Ficlatuzumab At The 2017 ASCO Annual Meeting 6/6/2017 8:11:14 AM
AVEO Oncology (AVEO) Announces Completion Of A CHMP Oral Explanation For Tivozanib As A Treatment Of First-Line Renal Cell Carcinoma 5/19/2017 6:16:16 AM
AVEO Oncology (AVEO) Announces Appointment Of Matthew Dallas As Chief Financial Officer 5/16/2017 8:43:10 AM
AVEO Oncology (AVEO) Issues Statement Regarding The Passing Of Lead Director Henri A. Termeer 5/15/2017 8:04:40 AM
AVEO Oncology (AVEO) Announces Receipt Of USPTO Notice Of Allowance Related To AV-353 5/8/2017 6:12:49 AM